A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated
variants with diverse genomic and biological data sets to provide insight into …

Objective To examine the association of cardiovascular events with tumour necrosis factor (TNF)
α antagonist use compared with non-biological disease-modifying antirheumatic drug (…

Background Cardiovascular (CV) disease has a major impact on patients with rheumatoid
arthritis (RA), however, the relative contributions of traditional CV risk factors and markers of …

Objective To determine the relationship of disease activity to infections in patients with
rheumatoid arthritis (RA). Methods From the CORRONA database, the incidence of physician-…

Introduction: Potential hepatotoxicity associated with disease-modifying antirheumatic drugs
(DMARDs) requires laboratory monitoring. In patients with rheumatoid arthritis (RA) or …

Objective. The ability of antiinflammatory strategies to alter cardiovascular risk has not been
rigorously examined. Colchicine is an antiinflammatory agent that affects macrophages, …

PURPOSE: Randomized controlled trials (RCTs) have demonstrated the efficacy of biologic
agents in the treatment of rheumatic diseases. However, results from RCTs may not be …

MicroRNAs (miRNAs) represent a class of non-coding RNA molecules playing pivotal roles
in cellular and developmental processes. miRNAs modulate the expression of multiple target …

… Jeffrey D Greenberg1, … Correspondence to Jeffrey D Greenberg, New York University
Hospital for Joint Diseases, Department of Rheumatology, 301 East 17th Street, suite 1410, New …

Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients …